Advertisement
Dr. Budimir S. Drakulic, Signalife's Chief Technology Officer commented:"This acquisition is very important for Signalife's manufacturingcapabilities. We have a great business relationship with HTG-Ventrex and areglad that they are now part of Medical Systems Division of Parker's SealGroup. Ventrex, Hi-Tech, and now Parker Hannifin remain totally committed toSignalife and its product's success."
Advertisement
About Signalife
Signalife, Inc. is a life sciences company focused on the monitoring,detection and prevention of disease through continuous biomedical signalmonitoring. Signalife uses its patented signal technology to design anddevelop medical devices, therapies and/or technologies that simplify andreduce the costs of cardiovascular disease.
Signalife, Inc. is traded on the American Stock Exchange under the symbolSGN. More information is located at www.signalife.com. Clear Data. TrustedResults.
Caution Regarding Forward-Looking Statements
Statements in this release that are not strictly historical are "forward-looking" statements. Forward-looking statements involve known and unknownrisks, which may cause Signalife's actual results in the future to differmaterially from expected results. Factors which could cause or contribute tosuch differences include, but are not limited to, failure to complete thedevelopment and introduction of heart monitoring and other biomedical devicesincorporating Signalife's technology, failure to obtain federal or state orgovernmental or international regulatory approvals governing heart monitoringand other biomedical devices incorporating Signalife's technology, failure toobtain import and export capabilities in the various countries containingbuyers and resellers and hospitals and clinics and doctors for the Signalifedevices, inability to obtain physician, patient or insurance acceptance of forheart monitoring and other biomedical incorporating Signalife's technology,and the unavailability of financing to complete management's plans andobjectives, including the development of heart monitoring and other biomedicalincorporating Signalife's technology. These risks are qualified in theirentirety by cautionary language and risk factors set forth and to be furtherdescribed in Signalife's filings with the Securities and Exchange Commission.
SOURCE Signalife, Inc.
